PYC Therapeutics Income Statement

Financials in millions AUD. Fiscal year is July - June.

Millions AUD. Fiscal year is Jul - Jun.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Jun '25 Jun 30, 2025	Jun '24 Jun 30, 2024	Jun '23 Jun 30, 2023	Jun '22 Jun 30, 2022	Jun '21 Jun 30, 2021
Other Revenue	20.56	23.49	22.06	15.81	16.04	3.07
Revenue	20.56	23.49	22.06	15.81	16.04	3.07
Revenue Growth (YoY)	-17.73%	6.50%	39.56%	-1.47%	421.83%	28.33%
Gross Profit	20.56	23.49	22.06	15.81	16.04	3.07
Selling, General & Admin	7.68	7.07	4.51	4.09	6.3	7.83
Research & Development	65.05	70.05	56.41	35.15	24.03	14
Operating Expenses	72.73	77.12	60.92	39.24	30.33	21.83
Operating Income	-52.17	-53.63	-38.86	-23.43	-14.29	-18.76
Interest Expense	-0.06	-0.06	-0.05	-0.03	-0.03	-0.04
Interest & Investment Income	3.96	2.68	0.8	0.08	0.02	0.11
Currency Exchange Gain (Loss)	-	-	-	-	-	0
EBT Excluding Unusual Items	-48.27	-51.01	-38.11	-23.38	-14.29	-18.69
Gain (Loss) on Sale of Assets	-	-	-	0.02	-	-
Other Unusual Items	-	-	-	-	-	0.06
Pretax Income	-48.27	-51.01	-38.11	-23.36	-14.29	-18.63
Earnings From Continuing Operations	-48.27	-51.01	-38.11	-23.36	-14.29	-18.63
Minority Interest in Earnings	0.71	0.71	0.39	0.57	0.43	0.86
Net Income	-47.56	-50.3	-37.73	-22.79	-13.86	-17.77
Net Income to Common	-47.56	-50.3	-37.73	-22.79	-13.86	-17.77
Shares Outstanding (Basic)	559	501	394	321	318	309
Shares Outstanding (Diluted)	559	501	394	321	318	309
Shares Change (YoY)	27.58%	27.16%	22.59%	0.93%	2.89%	12.58%
EPS (Basic)	-0.09	-0.10	-0.10	-0.07	-0.04	-0.06
EPS (Diluted)	-0.09	-0.10	-0.10	-0.07	-0.04	-0.06
Free Cash Flow	-66.22	-52.54	-38.9	-24.91	-22.17	-12.38
Free Cash Flow Per Share	-0.12	-0.10	-0.10	-0.08	-0.07	-0.04
Gross Margin	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
Operating Margin	-253.75%	-228.26%	-176.15%	-148.24%	-89.05%	-610.16%
Profit Margin	-231.33%	-214.11%	-171.02%	-144.18%	-86.41%	-577.93%
Free Cash Flow Margin	-322.07%	-223.61%	-176.32%	-157.61%	-138.19%	-402.76%
EBITDA	-51.41	-52.88	-38.12	-22.8	-13.69	-18.33
EBITDA Margin	-250.05%	-225.06%	-172.80%	-144.25%	-85.31%	-
D&A For EBITDA	0.76	0.75	0.74	0.63	0.6	0.42
EBIT	-52.17	-53.63	-38.86	-23.43	-14.29	-18.76
EBIT Margin	-253.75%	-228.26%	-176.15%	-148.24%	-89.05%	-
Revenue as Reported	24.52	26.17	22.86	15.91	16.07	3.24

Updated Dec 31, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.